The enzyme belongs to the aci-reductone dioxygenase family of metal-binding enzymes, which are involved in methionine salvage. This enzyme may regulate mRNA processing in the nucleus, and may carry out different functions depending on its localization.
ADI1 is capable for supporting hepatitis C virus replication in an otherwise non-permissive cell line.[4] Mouse hepatoma cells coexpressing human CD81 and ADI1/Sip-L supported HCV infection and replication.[5] Human ADI1//Sip-L over-expression in 293 cells enhances cell entry but not replication of HCV.[6][7]
References
↑Uekita T, Gotoh I, Kinoshita T, Itoh Y, Sato H, Shiomi T, Okada Y, Seiki M (Mar 2004). "Membrane-type 1 matrix metalloproteinase cytoplasmic tail-binding protein-1 is a new member of the Cupin superfamily. A possible multifunctional protein acting as an invasion suppressor down-regulated in tumors". J Biol Chem. 279 (13): 12734–43. doi:10.1074/jbc.M309957200. PMID14718544.
↑Hirano W, Gotoh I, Uekita T, Seiki M (Jun 2005). "Membrane-type 1 matrix metalloproteinase cytoplasmic tail binding protein-1 (MTCBP-1) acts as an eukaryotic aci-reductone dioxygenase (ARD) in the methionine salvage pathway". Genes Cells. 10 (6): 565–74. doi:10.1111/j.1365-2443.2005.00859.x. PMID15938715.
↑Yeh CT, Lai HY, Yeh YJ, Cheng JC (2008). "Hepatitis C virus infection in mouse hepatoma cells co-expressing human CD81 and Sip-L". Biochem Biophys Res Commun. 372 (1): 157–61. doi:10.1016/j.bbrc.2008.05.018. PMID18474223.
↑Cheng JC, Yeh YJ, Pai LM, Chang ML, Yeh CT (2009). "293 cells over-expressing human ADI1 and CD81 are permissive for serum-derived hepatitis C virus infection". J. Med. Virol. 81 (9): 1560–8. doi:10.1002/jmv.21495. PMID19626614.
↑Hwang DR, Lai HY, Chang ML, Hsu JT, Yeh CT (2005). "Emergence of mutation clusters in the HCV genome during sequential viral passages in Sip-L expressing cells". J Virol Methods. 129 (2): 170–7. doi:10.1016/j.jviromet.2005.05.026. PMID16005986.
Maruyama K, Sugano S (1994). "Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides". Gene. 138 (1–2): 171–4. doi:10.1016/0378-1119(94)90802-8. PMID8125298.
Suzuki Y, Yoshitomo-Nakagawa K, Maruyama K, Suyama A, Sugano S (1997). "Construction and characterization of a full length-enriched and a 5'-end-enriched cDNA library". Gene. 200 (1–2): 149–56. doi:10.1016/S0378-1119(97)00411-3. PMID9373149.
Yamada S, Ohira M, Horie H, Ando K, Takayasu H, Suzuki Y, Sugano S, Hirata T, Goto T, Matsunaga T, Hiyama E, Hayashi Y, Ando H, Suita S, Kaneko M, Sasaki F, Hashizume K, Ohnuma N, Nakagawara A (2004). "Expression profiling and differential screening between hepatoblastomas and the corresponding normal livers: identification of high expression of the PLK1 oncogene as a poor-prognostic indicator of hepatoblastomas". Oncogene. 23 (35): 5901–11. doi:10.1038/sj.onc.1207782. PMID15221005.
Gotoh I, Uekita T, Seiki M (2007). "Regulated nucleo-cytoplasmic shuttling of human aci-reductone dioxygenase (hADI1) and its potential role in mRNA processing". Genes Cells. 12 (1): 105–17. doi:10.1111/j.1365-2443.2006.01035.x. PMID17212658.
Ewing RM, Chu P, Elisma F, Li H, Taylor P, Climie S, McBroom-Cerajewski L, Robinson MD, O'Connor L, Li M, Taylor R, Dharsee M, Ho Y, Heilbut A, Moore L, Zhang S, Ornatsky O, Bukhman YV, Ethier M, Sheng Y, Vasilescu J, Abu-Farha M, Lambert JP, Duewel HS, Stewart II, Kuehl B, Hogue K, Colwill K, Gladwish K, Muskat B, Kinach R, Adams SL, Moran MF, Morin GB, Topaloglou T, Figeys D (2007). "Large-scale mapping of human protein-protein interactions by mass spectrometry". Mol. Syst. Biol. 3 (1): 89. doi:10.1038/msb4100134. PMC1847948. PMID17353931.
